Tasly Pharmaceuticals contributed to a series C round for the immunotherapy developer, a year after backing its $150m series B.
China-based immunotherapy developer I-Mab Biopharma closed a $220m series C round on Friday that included Tasly Capital, the corporate venture capital subsidiary of pharmaceutical company Tasly Pharmaceuticals.
The round was led by Hony Capital, the private equity firm formed by conglomerate Legend Holdings, and also featured Hillhouse Capital, Hopu Investments, CDH Investment, Ally Bridge Group, C-Bridge Capital and the Singapore state-owned EDBI.
Formed through the March 2017 merger of biologics technology developers Third Venture Biotech and Tasgen Bio, I-Mab is…